A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
Authors' conclusion
Clinical efficacy/effectiveness, safety, and HRQoL outcomes in adults with acromegaly were similar and costs lower with EDIs versus standard regimens. Physicians may consider acromegaly treatment at EDIs, especially for patients with good disease control.
Study context
- Population
- Adults with acromegaly; longitudinal/cross-sectional studies; MEDLINE/Embase/Cochrane Library (2001–June 2021) and key congresses (2018–2021)27 studies · 35 publications
- Comparison
- Extended dosing intervals (EDIs) vs standard dosing of pharmacological acromegaly treatments
- Outcome
- IGF-I control with EDIs
Main finding
As reported in the abstract
- Maintenance of normal IGF-I in ≥ 70% of patients with LAN (1 study), OCT (1 study) and pegvisomant monotherapy (1 study)
- Achievement of normal IGF-I in ≥ 70% of patients with LAN (3 studies) and pegvisomant + somatostatin receptor ligands (SRLs) (4 studies)
- Studies by treatment: 3 pegvisomant monotherapy, 11 pegvisomant + SRLs, 9 LAN, 4 OCT; none on cabergoline, PAS or oral octreotide at EDIs
Further findings
Patient preference, health-related quality of life (HRQoL) and costs
- Patients preferred and were satisfied with EDIs
- HRQoL maintained and cost savings with EDIs vs standard regimens
Safety
- Safety profiles similar across EDI and standard regimens
Original publication
A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly. Pituitary. Published 29 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →